Benzinga | Sep 29, 2020 07:53AM EDT

Guggenheim Initiates Coverage On Soleno Therapeutics with Buy Rating, Announces Price Target of $8

Guggenheim initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Buy rating and announces Price Target of $8.